## **EAST Search History**

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	6844	(435/7.2,7.1).CCLS.	USPAT; EPO	OR	OFF	2006/03/06 10:13
L2	2470	(436/514,547,548).CCLS.	USPAT; EPO	OR	OFF	2006/03/06 10:14
L3	887	PDGF near3 (alpha or beta)	USPAT; EPO	OR	OFF	2006/03/06 10:14
L4	240	PDGF near3 (alpha or beta) near3 receptor	USPAT; EPO	OR	OFF	2006/03/06 10:14
L5	45	l4 same antibody	USPAT; EPO	OR	OFF	2006/03/06 10:14
L6	25	l4 same antibody same (AA or BB or AB)	USPAT; EPO	OR	OFF	2006/03/06 10:15

```
Welcome to STN International! Enter x:x
LOGINID: ssspta1641cxc
PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2
* * * * * * * * * *
                     Welcome to STN International
NEWS 1
                 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2
                 "Ask CAS" for self-help around the clock
NEWS 3 DEC 05 CASREACT(R) - Over 10 million reactions available
NEWS 4 DEC 14 2006 MeSH terms loaded in MEDLINE/LMEDLINE
NEWS 5 DEC 14 2006 MeSH terms loaded for MEDLINE file segment of TOXCENTER
NEWS 6 DEC 14 CA/Caplus to be enhanced with updated IPC codes
NEWS 7 DEC 21 IPC search and display fields enhanced in CA/CAplus with the
                 IPC reform
NEWS 8 DEC 23 New IPC8 SEARCH, DISPLAY, and SELECT fields in USPATFULL/
                 USPAT2
NEWS 9 JAN 13
                 IPC 8 searching in IFIPAT, IFIUDB, and IFICDB
NEWS 10 JAN 13 New IPC 8 SEARCH, DISPLAY, and SELECT enhancements added to
                 INPADOC
NEWS 11 JAN 17 Pre-1988 INPI data added to MARPAT
NEWS 12 JAN 17 IPC 8 in the WPI family of databases including WPIFV
NEWS 13 JAN 30 Saved answer limit increased
NEWS 14 JAN 31 Monthly current-awareness alert (SDI) frequency
                 added to TULSA
NEWS 15 FEB 21 STN AnaVist, Version 1.1, lets you share your STN AnaVist
                 visualization results
NEWS 16 FEB 22 Status of current WO (PCT) information on STN
NEWS 17 FEB 22 The IPC thesaurus added to additional patent databases on STN
NEWS 18 FEB 22 Updates in EPFULL; IPC 8 enhancements added
NEWS 19 FEB 27 New STN AnaVist pricing effective March 1, 2006
NEWS 20 FEB 28 MEDLINE/LMEDLINE reload improves functionality
NEWS 21 FEB 28 TOXCENTER reloaded with enhancements
NEWS 22 FEB 28 REGISTRY/ZREGISTRY enhanced with more experimental spectral
                 property data
NEWS 23 MAR 01
                 INSPEC reloaded and enhanced
NEWS 24 MAR 03 Updates in PATDPA; addition of IPC 8 data without attributes
NEWS EXPRESS
              FEBRUARY 15 CURRENT VERSION FOR WINDOWS IS V8.01a,
              CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0jc(jp),
              AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005.
              V8.0 AND V8.01 USERS CAN OBTAIN THE UPGRADE TO V8.01a AT
              http://download.cas.org/express/v8.0-Discover/
NEWS HOURS
              STN Operating Hours Plus Help Desk Availability
NEWS INTER
              General Internet Information
NEWS LOGIN
              Welcome Banner and News Items
NEWS PHONE
              Direct Dial and Telecommunication Network Access to STN
NEWS WWW
              CAS World Wide Web Site (general information)
```

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

```
FILE 'HOME' ENTERED AT 10:17:18 ON 06 MAR 2006
=> file .meeting
'EVENTLINE' IS NOT A VALID FILE NAME
Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files
that are available. If you have requested multiple files, you can
specify a corrected file name or you can enter "IGNORE" to continue
accessing the remaining file names entered.
ENTER A FILE NAME OR (IGNORE):ignore
'MEDICONF' IS NOT A VALID FILE NAME
Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files
that are available. If you have requested multiple files, you can
specify a corrected file name or you can enter "IGNORE" to continue
accessing the remaining file names entered.
ENTER A FILE NAME OR (IGNORE): ignore
COST IN U.S. DOLLARS
                                                  SINCE FILE
                                                                  TOTAL
                                                       ENTRY
                                                                SESSION
FULL ESTIMATED COST
                                                        0.21
                                                                   0.21
FILE 'AGRICOLA' ENTERED AT 10:17:43 ON 06 MAR 2006
FILE 'BIOTECHNO' ENTERED AT 10:17:43 ON 06 MAR 2006
COPYRIGHT (C) 2006 Elsevier Science B.V., Amsterdam. All rights reserved.
FILE 'CONFSCI' ENTERED AT 10:17:43 ON 06 MAR 2006
COPYRIGHT (C) 2006 Cambridge Scientific Abstracts (CSA)
FILE 'HEALSAFE' ENTERED AT 10:17:43 ON 06 MAR 2006
COPYRIGHT (C) 2006 Cambridge Scientific Abstracts (CSA)
FILE 'IMSDRUGCONF' ENTERED AT 10:17:43 ON 06 MAR 2006
COPYRIGHT (C) 2006 IMSWORLD Publications Ltd.
FILE 'LIFESCI' ENTERED AT 10:17:43 ON 06 MAR 2006
COPYRIGHT (C) 2006 Cambridge Scientific Abstracts (CSA)
FILE 'PASCAL' ENTERED AT 10:17:43 ON 06 MAR 2006
Any reproduction or dissemination in part or in full,
by means of any process and on any support whatsoever
is prohibited without the prior written agreement of INIST-CNRS.
COPYRIGHT (C) 2006 INIST-CNRS. All rights reserved.
=> PDGF(3A) (alpha or beta) (3A) receptor
            9 FILE AGRICOLA
L1
           621 FILE BIOTECHNO
L2
L3
            16 FILE CONFSCI
             0 FILE HEALSAFE
T.4
             0 FILE IMSDRUGCONF
L5
L6
           394 FILE LIFESCI
           466 FILE PASCAL
TOTAL FOR ALL FILES
          1506 PDGF(3A) (ALPHA OR BETA) (3A) RECEPTOR
=> PDGF(3A) (alpha or beta) (3A) receptor (8A) antibody
L9
            0 FILE AGRICOLA
L10
            28 FILE BIOTECHNO
L11
            1 FILE CONFSCI
L12
            0 FILE HEALSAFE
```

TOTAL FOR ALL FILES

L13

L14

L15

L16 75 PDGF(3A) (ALPHA OR BETA) (3A) RECEPTOR (8A) ANTIBODY

0 FILE IMSDRUGCONF 23 FILE LIFESCI

23 FILE PASCAL

```
=> L16 and (AA or BB or AB)
L17
            0 FILE AGRICOLA
L18
            17 FILE BIOTECHNO
L19
            0 FILE CONFSCI
L20
            O FILE HEALSAFE
L21
            0 FILE IMSDRUGCONF
L22
            12 FILE LIFESCI
            15 FILE PASCAL
L23
TOTAL FOR ALL FILES
            44 L16 AND (AA OR BB OR AB)
=> 124 and affinity
             0 FILE AGRICOLA
             3 FILE BIOTECHNO
L26
            0 FILE CONFSCI
L27
L28
            O FILE HEALSAFE
L29
             0 FILE IMSDRUGCONF
             1 FILE LIFESCI
L30
             1 FILE PASCAL
L31
TOTAL FOR ALL FILES
             5 L24 AND AFFINITY
=> dup rem
ENTER L# LIST OR (END):132
DUPLICATE IS NOT AVAILABLE IN 'IMSDRUGCONF'.
ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE
PROCESSING COMPLETED FOR L32
              3 DUP REM L32 (2 DUPLICATES REMOVED)
L33
=> d 133 ibib abs total
      ANSWER 1 OF 3 BIOTECHNO COPYRIGHT 2006 Elsevier Science B.V. on STN
ACCESSION NUMBER:
                          1993:23335427 BIOTECHNO
TITLE:
                          Expression of platelet-derived growth factor \beta
                          receptor on human monocyte-derived macrophages and
                          effects of platelet-derived growth factor BB
                          dimer on the cellular function
AUTHOR:
                          Inaba T.; Shimano H.; Gotoda T.; Harada K.; Shimada
                          M.; Ohsuga J.-I.; Watanabe Y.; Kawamura M.; Yazaki Y.;
                          Yamada N.
CORPORATE SOURCE:
                          Third Dept. of Internal Medicine, Faculty of Medicine,
                          University of Tokyo, Hongo, Tokyo 113, Japan.
                          Journal of Biological Chemistry, (1993), 268/32
SOURCE:
                          (24353 - 24360)
                          CODEN: JBCHA3 ISSN: 0021-9258
DOCUMENT TYPE:
                          Journal; Article
COUNTRY:
                          United States
LANGUAGE:
                          English
SUMMARY LANGUAGE:
                          English
AN
      1993:23335427 BIOTECHNO
      Platelet-derived growth factor (PDGF) plays an important role in the
AB
      process of atherosclerosis which is characterized by the presence of
      macrophage-derived foam cells. In the present study, the induction of the mRNA of PDGF-\beta receptor was demonstrated during cell differentiation
      of human monocyte-macrophages, whereas no mRNA was detected in the cells
      during the early days of culture. Flow cytometry analysis using
      antibodies specific for PDGF-.beta.
      receptor and CD14 showed the presence of both PDGF-\beta
      receptor and CD14 on human monocyte-derived macrophages, whereas no
      PDGF-\beta receptor was detected on human monocytes 4 h after cell
      adhesion to a culture dish. In the binding assay of PDGF-BB on
      human monocyte-derived macrophages, a saturable and high affinity
      binding site with K(d) of 27.5 pM and B(max) of 23.3 fmol/mg of cell
      protein was demonstrated. When human monocytes were cultured in the
      presence of the protein kinase C inhibitor staurosporine, PDGF-\beta
      receptor induction was inhibited, and tetradecanoylphorbol acetate
      enhanced PDGF-\beta receptor expression in human monocyte-derived
```

macrophages, indicating that PDGF- $\beta$  receptor expression is associated with maturation and differentiation of monocyte-macrophages through the activation of protein kinase C. In response to PDGF-BB homodimer, PDGF- $\beta$  receptor was phosphorylated, and thymidine uptake and inositol trisphosphate production were stimulated in monocyte-derived macrophages. Furthermore, PDGF-BB suppressed the production of macrophage colony-stimulating factor in macrophages. The expression of PDGF- $\beta$  receptor on human monocyte-derived macrophages suggests that PDGF influences the process of atherosclerosis by regulating the function of macrophages as well as smooth muscle cells in the vascular wall.

ANSWER 2 OF 3 BIOTECHNO COPYRIGHT 2006 Elsevier Science B.V. on STN L33

DUPLICATE

ACCESSION NUMBER: 1993:23186325 BIOTECHNO

TITLE: Conservation in sequence and affinity of human and rodent PDGF ligands and receptors

AUTHOR: Herren B.; Weyer K.A.; Rouge M.; Lotscher P.; Pech M. CORPORATE SOURCE: Pharma Division, Preclinical Research, F. Hoffmann-La

Roche, Grenzacherstrasse 124, CH-4002 Basel,

Switzerland.

SOURCE: Biochimica et Biophysica Acta - Gene Structure and

Expression, (1993), 1173/3 (294-302)

CODEN: BBGSD5 ISSN: 0167-4781

DOCUMENT TYPE: Journal; Article

COUNTRY: Netherlands LANGUAGE: English SUMMARY LANGUAGE: English BIOTECHNO AN 1993:23186325

AB Platelet-derived growth factor (PDGF) consists of two chains, PDGF-A

and-B, which activate as homo- or heterodimers two receptors,

 $\alpha$  and . beta.. To test PDGF function in vivo we have generated neutralizing monoclonal antibodies. When analyzed with rat PDGFs only antibodies raised against human PDGF-AA showed cross-species activity. This correlated with complete amino acid sequence conservation of PDGF-A whereas rat PDGF-B differed in six positions when cloned rat PDGF cDNAs were compared with their human homologs within the receptor binding region. Extracellular domains of cloned rat PDGF  $\alpha$ - and  $\beta$ -receptor cDNAs did not reflect this difference in cross-species ligand conservation. When rat extracellular domains were expressed as soluble proteins they bound human PDGF-BB with high affinity after immobilization of the purified proteins on solid phase. Dissociation constants were identical to those of their human homologs. Thus, high affinity binding of human PDGP-BB to extracellular domains does not depend on

species origin but only on receptor type.

T.33 ANSWER 3 OF 3 BIOTECHNO COPYRIGHT 2006 Elsevier Science B.V. on STN DUPLICATE

ACCESSION NUMBER: 1992:22087723 BIOTECHNO

TITLE: Characterization of platelet-derived growth factor and

platelet-derived growth factor receptor expression in

asbestos-induced rat mesothelioma

AUTHOR: Walker C.; Bermudez E.; Stewart W.; Bonner J.; Molloy

C.J.; Everitt J.

CORPORATE SOURCE: Chemical Industry Institute of Toxicology, Research

Triangle Park, NC 27709, United States. Cancer Research, (1992), 52/2 (301-306)

SOURCE:

CODEN: CNREA8 ISSN: 0008-5472

DOCUMENT TYPE: Journal; Article COUNTRY:

United States

LANGUAGE: English SUMMARY LANGUAGE: English AN 1992:22087723 BIOTECHNO

AB Although altered expression of platelet-derived growth factor (PDGF) is a hallmark of human mesothelioma, expression of PDGF receptors has not been characterized in this cell type. In addition, the expression of this growth factor and its cognate receptor in rodent mesothelioma has not been investigated. In this study, examination of transformed mesothelial

cells derived from asbestos-induced rat mesotheliomas revealed that these cells expressed high affinity PDGF receptors (K(d) = 0.5 nM) and receptor number was 1.6 x 10.sup.5/cell. Western analysis using antibodies specific for either the  $\alpha$ -type or . beta .-type PDGF receptor and Northern analysis using probes specific for  $\alpha$ - and  $\beta$ -type receptor RNA transcripts indicated that these cells expressed  $\beta$ -type PDGF receptors but that a-type receptors could not be detected. However, when the mesothelioma-derived cells were examined for the expression of PDGF, no expression of this growth factor could be detected. The transformed cells expressed no detectable A- or B-chain PDGF RNA transcripts; and using a competitive enzyme immunoassay specific for isoforms containing the B chain of PDGF and a sandwich enzyme-linked immunosorbent assay specific for A-chain-containing isoforms, neither AA, nor AB, nor BB isoforms of this growth factor could be detected in medium conditioned by these cells. The absence of alterations in PDGF expression in rat mesothelioma, in contrast to the data for the human disease, suggests that the production of this growth factor by transformed mesothelial cells may be species specific.

ENTER A FILE NAME OR (IGNORE):ignore

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY SESSION

**FULL ESTIMATED COST** 

0.21 0.21

FILE 'AGRICOLA' ENTERED AT 09:56:13 ON 06 JAN 2006

FILE 'BIOTECHNO' ENTERED AT 09:56:13 ON 06 JAN 2006 COPYRIGHT (C) 2006 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'CONFSCI' ENTERED AT 09:56:13 ON 06 JAN 2006 COPYRIGHT (C) 2006 Cambridge Scientific Abstracts (CSA)

FILE 'HEALSAFE' ENTERED AT 09:56:13 ON 06 JAN 2006 COPYRIGHT (C) 2006 Cambridge Scientific Abstracts (CSA)

FILE 'IMSDRUGCONF' ENTERED AT 09:56:13 ON 06 JAN 2006 COPYRIGHT (C) 2006 IMSWORLD Publications Ltd.

FILE 'LIFESCI' ENTERED AT 09:56:13 ON 06 JAN 2006 COPYRIGHT (C) 2006 Cambridge Scientific Abstracts (CSA)

FILE 'PASCAL' ENTERED AT 09:56:13 ON 06 JAN 2006 Any reproduction or dissemination in part or in full, by means of any process and on any support whatsoever is prohibited without the prior written agreement of INIST-CNRS. COPYRIGHT (C) 2006 INIST-CNRS. All rights reserved.

=> (alpha or beta)(1A)(PDGF)(1A)receptor

- L1 9 FILE AGRICOLA
- L2 544 FILE BIOTECHNO
- L3 15 FILE CONFSCI
- L4 0 FILE HEALSAFE
- L5 0 FILE IMSDRUGCONF
- L6 349 FILE LIFESCI
- L7 385 FILE PASCAL

## TOTAL FOR ALL FILES

L8 1302 (ALPHA OR BETA)(1A)(PDGF)(1A) RECEPTOR

=> 18(10A)antibody

- L9 0 FILE AGRICOLA
- L10 26 FILE BIOTECHNO
- L11 1 FILE CONFSCI
- L12 0 FILE HEALSAFE
- L13 0 FILE IMSDRUGCONF

L14 21 FILE LIFESCI L15 16 FILE PASCAL

TOTAL FOR ALL FILES

L16 64 L8(10A) ANTIBODY

=> 116 and isoform

L17 0 FILE AGRICOLA

L18 6 FILE BIOTECHNO

L19 0 FILE CONFSCI

L20 0 FILE HEALSAFE

L21 0 FILE IMSDRUGCONF

L22 3 FILE LIFESCI

L23 3 FILE PASCAL

TOTAL FOR ALL FILES

L24 12 L16 AND ISOFORM

=> dup rem

ENTER L# LIST OR (END):124

DUPLICATE IS NOT AVAILABLE IN 'IMSDRUGCONF'.

ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIOUE

PROCESSING COMPLETED FOR L24

L25 8 DUP REM L24 (4 DUPLICATES REMOVED)

=> d l25 ibib abs total

L25 ANSWER 1 OF 8 PASCAL COPYRIGHT 2006 INIST-CNRS. ALL RIGHTS RESERVED. on

STN

ACCESSION NUMBER:

1998-0080771 PASCAL

COPYRIGHT NOTICE:

Copyright .COPYRGT. 1998 INIST-CNRS. All rights

reserved.

TITLE (IN ENGLISH): Platelet-derived growth factor .beta.-receptors can

both promote and inhibit chemotaxis in human vascular

smooth muscle cells

AUTHOR:

CLUNN G. F.; REFSON J. S.; LYMN J. S.; HUGHES A. D.

CORPORATE SOURCE:

Department of Clinical Pharmacology, Imperial College

School of Medicine at St Mary's, London, United

Kingdom

SOURCE:

Arteriosclerosis, thrombosis, and vascular biology,

(1997), 17(11), 2622-2629, 25 refs.

ISSN: 1079-5642

DOCUMENT TYPE:

Journal

**BIBLIOGRAPHIC LEVEL:** 

Analytic

COUNTRY:

United States

LANGUAGE:

English

AVAILABILITY:

INIST-19104, 354000077257250390

AN 1998-0080771 PASCAL

CP Copyright .COPYRGT. 1998 INIST-CNRS. All rights reserved.

AB The effect of the three platelet-derived growth factor (PDGF) isoforms AA, AB, and BB on migration was investigated in cultured human saphenous vein smooth muscle cells. The modified Boyden chamber technique yielded efficacies BB'AB, AA=0. However, the BB concentration-response relationship displayed a pronounced peak. occurring between 1 and 10 ng/mL, with no response above this range. Checkerboard analysis showed that the promotion of migration at low concentrations was chemotactic in nature but that the downturn was independent of gradient. Furthermore, at high concentrations BB was able to prevent chemotaxis induced by fetal calf serum and epidermal growth factor (EGF). Experiments using low concentrations of BB in combination with high concentrations of AA to saturate PDGF .alpha .-receptors in the presence and absence of a neutralizing antibody to .alpha.-receptors revealed that .alpha.-receptor activation induced partial inhibition of chemotaxis but this did not account for the inhibition of migration by high concentrations of BB. Despite possessing no significant chemotactic action itself, high concentrations of the AB isoform completely inhibited BB induced chemotaxis. Taken together these results suggest that the chemotactic signal induced by PDGF is dominated by PDGF .beta.-receptors and switches from positive at low concentrations to negative at higher concentrations. Stimulation of DNA synthesis by the three isoforms (as measured by [.sup.3H] thymidine incorporation) yielded saturable responses for the AB and BB isoforms, with similar efficacy and weak or no response for the AA isoform. Concentration-dependent patterns of tyrosine phosphorylation of certain proteins mirrored the form of the chemotactic response and suggest one possible underlying regulatory mechanism to account for the disparity between PDGF-induced chemotaxis and DNA synthesis.

L25 ANSWER 2 OF 8 BIOTECHNO COPYRIGHT 2006 Elsevier Science B.V. on STN

**DUPLICATE** 

**ACCESSION NUMBER:** 

1995:25247395 BIOTECHNO

TITLE:

Elevated D-glucose concentrations modulate TGF-.beta.1

synthesis by human cultured renal proximal tubular cells. The permissive role of platelet- derived growth

factor

AUTHOR:

Phillips A.O.; Steadman R.; Topley N.; Williams J.D.

**CORPORATE SOURCE:** 

Institute of Nephrology, Cardiff Royal Infirmary, New

Port Road, Cardiff CF2 1SZ, United Kingdom.

SOURCE:

American Journal of Pathology, (1995), 147/2 (362-374)

CODEN: AJPAA4 ISSN: 0002-9440

DOCUMENT TYPE: Journal; Article

COUNTRY: United States LANGUAGE: English

SUMMARY LANGUAGE: English AN 1995:25247395 BIOTECHNO

AB Interstitial fibrosis is a marker of progression of renal impairment in diabetic nephropathy. Transforming growth factor (TGF)-, beta, 1 is one of a group of pro-fibrotic cytokines and growth factors that have been associated with the development of interstitial fibrosis. We have examined the modulating influence of glucose on the production of TGF-.beta. 1 by cultured human proximal tubular cells. Incubation of growth-arrested human proximal tubular cells (HPTC) (72 hours in serum free medium) in 25 mmol/L D-glucose resulted in increased expression of TGF-.beta.1 mRNA (as assessed by reverse transcription polymerase chain reaction). This was apparent after 6 hours and increased up to 120 hours exposure. TGF-.beta.1 secretion, however, as measured by specific enzyme-linked immunoassay, was unaffected by exposure to 25 mmol/L D-glucose. Sequential stimulation of HPTC, first with 25 mmol/L D-glucose for 48 hours and then with platelet-derived growth factor (PDGF) isoforms, resulted in a dose-dependent secretion of TGF-.beta.1. Pre-exposure to 5 mmol/L D-glucose or 25 mmol/L L-glucose did not prime for TGF-.beta.1 release. At 50 ng/ml PDGF this effect was greatest for the AA isoform (AA 31.4.+-. 7.1, AB 20.98.+-. 89, BB 7.8.+-. 2.2, P < 0.05 for all versus control, n = 3, mean .+-. SEM ng/10.sup.6 cells/24 hours). These effects were blocked by the addition of antibody to the PDGF .alpha.-receptor

. TGF-.beta.1 secretion was inhibited in a dose-dependent manner by pretreatment with cyclohexamide, but was not affected by pretreatment with actinomycin D. Stimulation of HPTC with a single dose of PDGF induced TGF-.beta.1 mRNA: however, only after application of a second dose of PDGF (after TGF-.beta.1 mRNA induction) did TGF-.beta.1 protein secretion occur. We also demonstrated that PDGF stimulation of HPTC induced an inherently more stable TGF-.beta.1 mRNA transcript. These findings demonstrate that elevated D- glucose concentration alone is insufficient to lead to increased TGF-.beta.1 secretion by HPTC despite increased mRNA expression. However, application of a second stimulus such as PDGF, when TGF-.beta.1 mRNA expression is increased, leads to increased protein synthesis and secretion of TGF-.beta.1. This implies that elevated glucose concentrations might prime proximal tubular cells for TGF-.beta.1 synthesis and thus contribute to the development of interstitial fibrosis.

L25 ANSWER 3 OF 8 BIOTECHNO COPYRIGHT 2006 Elsevier Science B.V. on STN

**DUPLICATE** 

ACCESSION NUMBER: 1993:23162254 BIOTECHNO

TITLE: Divergent regulation of phosphatidylinositol 3-kinase

p85.alpha. and p85.beta. isoforms upon T

cell activation

AUTHOR: Reif K.; Gout I.; Waterfield M.D.; Cantrell D.A.

CORPORATE SOURCE: Lymphocyte Activation Laboratory, Imperial Cancer

Research Fund, 44 Lincoln's Inn Fields, London WC2A

3PX, United Kingdom.

SOURCE:

Journal of Biological Chemistry, (1993), 268/15

(10780-10788)

CODEN: JBCHA3 ISSN: 0021-9258

DOCUMENT TYPE:

Journal; Article

COUNTRY:

United States

LANGUAGE:

English

SUMMARY LANGUAGE: English AN 1993:23162254 BIOTECHNO

AB Phosphatidylinositol (PtdIns) 3-kinase is composed of a catalytic p110 subunit and a regulatory p85 subunit. A synthetic phosphopeptide corresponding to the kinase insert of the human PDGF. beta. subunit receptor and monoclonal antibodies raised against the two described p85 isoforms, p85.alpha. and p85.beta. were used to isolate PtdIns 3-kinase from

human T lymphocytes. We demonstrate that T cells express both p85.alpha. and p85.beta. proteins. Both isoforms tightly associate with a p110 protein and with PtdIns 3-kinase activity in T cells. Upon triggering of the T cell antigen receptor (TCR)/CD3 complex or activation of protein kinase C (PKC) the p110 protein complexed to p85.alpha. becomes rapidly phosphorylated exclusively on serine residues. p85.alpha. does not appear to undergo a change in its basal serine phosphorylation during T cell activation. In contrast, stimulation of the TCR/CD3 complex or PKC, results in a marked and rapid increase in phosphorylation of p85.beta. on threonine residues. These data show that PtdIns 3-kinase can be a substrate for serine/threonine kinases in T cells. The differential phosphorylation of p85.alpha. and p85.beta. reveals the potential for divergent regulation and function of these two PtdIns 3-kinase isoforms during T cell activation.

L25 ANSWER 4 OF 8 BIOTECHNO COPYRIGHT 2006 Elsevier Science B.V. on STN

ACCESSION NUMBER:

1993:23343568 BIOTECHNO

TITLE:

Involvement of PKC-.alpha. in PDGF-mediated mitogenic

signaling in human mesangial cells

AUTHOR:

Choudhury G.G.; Biswas P.; Grandaliano G.; Abboud H.E. RCE: Division of Nephrology, Dept. of Medicine, Univ. of

CORPORATE SOURCE:

Texas Health Science Center, 7703 Floyd Curl Drive, San

Antonio, TX 78284-7882, United States.

SOURCE:

American Journal of Physiology - Renal Fluid and Electrolyte Physiology, (1993), 265/5 34-5 (F634-F642)

CODEN: AJPFDM ISSN: 0002-9513

**DOCUMENT TYPE:** 

Journal; Article

COUNTRY:

United States

LANGUAGE:

English

**SUMMARY LANGUAGE:** 

English

AN 1993:23343568 BIOTECHNO

AB Platelet-derived growth factor (PDGF) is a potent mitogen for a variety of cells. The calcium/phospholipid-dependent protein kinase C (PKC) represents a major signal transduction pathway for many growth stimuli including PDGF. Various isoforms of PKC are differentially expressed in the same or in different cells and tissues, and diverse stimuli may selectively activate one or more PKC isoforms. We studied the effect of PDGF on DNA synthesis and on the activity of PKC in human mesangial cells and vascular pericytes in the glomerular microvascular bed. PKC activity was measured as the amount of phosphorylated myelin basic protein-derived peptide substrate in the absence and presence of an inhibitor, a peptide spanning the pseudosubstrate region of PKC. PDGF (15 ng/ml) stimulated PKC activity within 5 min, and the effect was sustained for 60 min. Pretreatment of mesangial cells with 1-(5- isoquinolinesulfonyl)-2-methylpiperazine (H-7), an inhibitor of PKC, abolished the stimulation of PKC and DNA synthesis in response to PDGF. This effect of H-7 was specific, because H-7 did not inhibit the tyrosine phosphorylation of the PDGF receptor in vivo when added to the cells or the in vitro kinase activity in the PDGF .beta.-receptor immunoprecipitates.

Utilizing isotype-specific antibodies against PKC-.alpha.,

-.beta., or -.gamma. for immunoprecipitation of PDGF-treated mesangial cell extracts, followed by assay of PKC activity, we demonstrated the activation of PKC-.alpha. only. Northern blot analysis of mRNA prepared from mesangial cells also revealed two transcripts, 3.7 kb and 1.8 kb, that hybridized with cDNA specific for PKC-.alpha.. Moreover, specific ribonuclease (RNase) protection assay using cRNAs specific for PKC-.alpha., -.beta., and -.gamma. as probes revealed predominantly the presence of PKC-.alpha. in mesangial cells. These studies demonstrate that in mesangial cells stimulation of DNA synthesis in response to PDGF is dependent on activation of PKC and that the .alpha.-isoform of this kinase may mediate the mitogenic effect of PDGF.

L25 ANSWER 5 OF 8 BIOTECHNO COPYRIGHT 2006 Elsevier Science B.V. on STN

DUPLICATE

**ACCESSION NUMBER:** 

1992:22087723 BIOTECHNO

TITLE:

Characterization of platelet-derived growth factor and platelet-derived growth factor receptor expression in

asbestos-induced rat mesothelioma

**AUTHOR:** 

Walker C.; Bermudez E.; Stewart W.; Bonner J.; Molloy

C.J.; Everitt J.

CORPORATE SOURCE:

Chemical Industry Institute of Toxicology, Research

Triangle Park, NC 27709, United States.

SOURCE:

Cancer Research, (1992), 52/2 (301-306)

CODEN: CNREA8 ISSN: 0008-5472

**DOCUMENT TYPE:** 

Journal; Article

COUNTRY:

United States

LANGUAGE:

**English** 

SUMMARY LANGUAGE:

GE: English

AN 1992:22087723 BIOTECHNO

AB Although altered expression of platelet-derived growth factor (PDGF) is a hallmark of human mesothelioma, expression of PDGF receptors has not been characterized in this cell type. In addition, the expression of this growth factor and its cognate receptor in rodent mesothelioma has not been investigated. In this study, examination of transformed mesothelial cells derived from asbestos-induced rat mesotheliomas revealed that these cells expressed high affinity PDGF receptors (K(d) = 0.5 nM) and receptor number was 1.6 x 10.sup.5/cell. Western analysis using antibodies specific for either the .alpha.-type or .beta.-type PDGF receptor and Northern analysis using probes specific for .alpha.- and .beta.-type receptor RNA transcripts indicated that these cells expressed .beta.-type PDGF receptors but that .alpha.-type receptors could not be detected. However, when the mesothelioma-derived cells were examined for the expression of PDGF, no expression of this growth factor could be detected. The transformed cells expressed no detectable A- or B-chain PDGF RNA transcripts; and using a competitive enzyme immunoassay specific for isoforms containing the B chain of PDGF and a sandwich enzyme-linked immunosorbent assay specific for A-chain-containing isoforms, neither AA, nor AB, nor BB isoforms of this growth factor could be detected in medium conditioned by these cells. The absence of alterations in PDGF expression in rat mesothelioma, in contrast to the data for the human disease, suggests that the production of this growth factor by transformed mesothelial cells may be species specific.

L25 ANSWER 6 OF 8 LIFESCI COPYRIGHT 2006 CSA on STN ACCESSION NUMBER: 93:8471 LIFESCI

TITLE:

Development distribution of platelet-derived growth factor

in the mouse central nervous system.

AUTHOR:

Hutchins, J.B.; Jefferson, V.E.

CORPORATE SOURCE: Dep. Anat., Univ. Mississippi Med. Cent., 2500 N. State St., Jackson, MS 39216-4505, USA

SOURCE:

DEV. BRAIN RES., (1992) vol. 67, no. 2, pp. 121-135.

**DOCUMENT TYPE:** 

Journal

FILE SEGMENT: N3 LANGUAGE: English

SUMMARY LANGUAGE: English

characterize the developmental changes in the distribution and relative quantity of platelet-derived growth factor (PDGF), an important mitogen and growth regulator for glial (and possibly neuronal) cells. PDGF exists as a dimer of two chains, A and B, and antibodies which are relatively specific for one chain or the other can be used to localize PDGF isoforms during development. We have also studied the distribution of PDGF receptor beta subunit ( PDGF-R beta )-like immunoreactivity using an antibody probe. All 3 isoforms of PDGF are found in neural structures during development, beginning at about the mid-point of embryogenesis. Immunoblotting studies confirm the presence of PDGF isoforms in brain during embryonic and postnatal development, with the distribution and relative abundance of each isoform appearing to be independently regulated. By E15, both PDGF isoform and PDGF receptor beta subunit immunoreactivity have declined to near-background levels in the sensory ganglia, while in the spinal cord and developing forebrain, levels of all PDGF-related proteins remain high.

AB Immunoblotting and immunohistochemical techniques have been used to

L25 ANSWER 7 OF 8 BIOTECHNO COPYRIGHT 2006 Elsevier Science B.V. on STN

ACCESSION NUMBER:

1991:21147700 BIOTECHNO

TITLE:

Ligand-induced interaction between .alpha.- and .beta.-type platelet-derived growth factor (PDGF) receptors: Role of receptor heterodimers in kinase

activation

**AUTHOR:** 

Kanakaraj P.; Raj S.; Khan S.A.; Bishayee S.

CORPORATE SOURCE:

Coriell Institute for Med. Res, 401 Haddon

Avenue, Camden, NJ 08103, United States.

SOURCE:

Biochemistry, (1991), 30/7 (1761-1767)

CODEN: BICHAW ISSN: 0006-2960

DOCUMENT TYPE:

Journal: Article

COUNTRY:

**United States** 

LANGUAGE:

English

SUMMARY LANGUAGE:

GE: English

AN 1991:21147700 BIOTECHNO

AB Two types of PDGF receptors have been cloned and sequenced. Both receptors are transmembrane glycoproteins with a ligand-stimulatable tyrosine kinase site. We have shown earlier that ligand-induced activation of the beta.-type PDGF receptor is due to the conversion of the monomeric form of the receptor to the dimeric form .cents.Bishayee et al. (1989) J. Biol. Chem. 264, 11699-11705!. In the present studies, we have established the ligand-binding specificity of two receptor types and

extended it further to investigate the ligand-induced association state of the .alpha.-receptor and the role of .alpha.-receptor in the activation of .beta.-receptor. These studies were conducted with cells that express one or the other type of PDGF receptor as well as with cells that express both types of receptors. Moreover, ligand-binding characteristics of the receptor were confirmed by immunoprecipitation of the receptor-.sup.1.sup.2.sup.5I-PDGF covalent complex with type-specific anti-PDGF receptor antibodies. These studies revealed that all three isoforms of PDGF binding to .alpha.-receptor, and such binding leads to dimerization as well as activation of the receptor. In contrast, .beta.-receptor can be activated only by PDGF BB and not by PDGF AB or PDGF AA. However, by using antipeptide antibodies that are specific for .alpha.- or .beta.-type PDGF receptor, we demonstrated that in the presence of .alpha.-receptor, .beta.-receptor kinase can be activated by PDGF AB. We present here direct evidence that strongly suggests that such PDGF AB induced activation of .beta.-receptor is due to the formation of a noncovalently linked .alpha.-.beta. receptor heterodimer.

L25 ANSWER 8 OF 8 BIOTECHNO COPYRIGHT 2006 Elsevier Science B.V. on STN

ACCESSION NUMBER:

1990:20240377 BIOTECHNO

TITLE:

Coexpression of the platelet-derived growth factor

(PDGF) B chain and the PDGF .beta. receptor in isolated pancreatic islet cells stimulates DNA

synthesis

AUTHOR:

Welsh M.; Claesson-Welsh L.; Hallberg A.; Welsh N.;

Betsholtz C.; Arkhammar P.; Nilsson T.; Heldin C.-H.;

Berggren P.-O.

CORPORATE SOURCE:

Department of Medical Cell, Biology, Uppsala

University, P.O. Box 571 BMC, S-75123 Uppsala, Sweden.

SOURCE:

Proceedings of the National Academy of Sciences of the

United States of America, (1990), 87/15 (5807-5811)

CODEN: PNASA6 ISSN: 0027-8424

DOCUMENT TYPE:

Journal: Article

COUNTRY:

United States

LANGUAGE:

English

SUMMARY LANGUAGE:

E: English

AN \1990:20240377 BIOTECHNO

AB Suspensions rich in pancreatic beta, cells were transfected by means of electroporation or by using the liposome technique with DNA constructs coding for the B chain of platelet-derived growth factor (PDGF) and the PDGF alpha, and beta, receptors to induce a mitotic response in this slowly replicating cell type. Transfection with the B-chain construct induced synthesis of the PDGF B-chain homodimer (PDGF-BB) as assessed by the presence of sup.1.sup.2.sup.5I-labeled PDGF-BB competing activity in

the conditioned medium of the transfected islet cells. Moreover, islet cells transfected with the PDGF .beta.receptor construct exhibited increased immunofluorescence staining with a PDGF .beta.-receptor antibody. These cells also displayed increased .sup.1.sup.2.sup.5I-labeled PDGF-BB binding compared with control transfected cells. Cotransfection with the B-chain construct or the addition of 10% fetal bovine serum or purified PDGF all induced DNA synthesis in islet cells transfected with the PDGF .beta.-receptor construct. Islet cells transfected with the PDGF .alpha,-receptor construct did not respond with stimulation of .cents..sup.3H!thymidine incorporation to any of the PDGF isoforms (PDGF-AA, -AB, or -BB). Cotransfection of the PDGF .alpha.- and .beta.-receptor constructs resulted in a loss of the DNA synthesis response to PDGF. The .beta. cells exhibited elevated levels of .cents..sup.3H!inositol trisphosphate after transfection with the B-chain and .beta.-receptor constructs. indicating activation of phospholipase C. Islet cells transfected with the different receptor constructs exhibited different patterns of tyrosine phosphorylation upon ligand activation. The results demonstrate that pancreatic islet cells can be stimulated to increase DNA synthesis by transfection with the PDGF .beta.-receptor gene, whereas cotransfection with the .alpha.-receptor gene may attenuate the growth response.